Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,099,920 | 968,492 | 681,879 | 812,688 | 1,033,024 |
| Marketable Securities | 1,680,315 | 1,656,157 | 1,689,403 | 1,626,694 | 1,373,254 |
| Receivables | 353,852 | 309,481 | 321,377 | 327,787 | 325,445 |
| Inventories | 75,987 | 83,981 | 93,988 | 89,146 | 95,771 |
| TOTAL | $3,355,424 | $3,172,856 | $2,988,607 | $2,982,697 | $2,985,452 |
| Non-Current Assets | |||||
| PPE Net | 506,997 | 517,159 | 523,460 | 526,057 | 525,591 |
| Investments And Advances | 68,592 | 49,391 | 49,390 | 49,391 | 49,390 |
| Other Non-Current Assets | 274,026 | 270,228 | 262,929 | 271,735 | 278,640 |
| TOTAL | $849,615 | $836,778 | $835,779 | $847,183 | $853,621 |
| Total Assets | $4,205,039 | $4,009,634 | $3,824,386 | $3,829,880 | $3,839,073 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 70,805 | 73,980 | 78,148 | 55,519 | 73,840 |
| Accrued Expenses | 946,168 | 808,643 | 698,865 | 713,013 | 713,094 |
| Other current liabilities | 90,516 | 61,963 | 46,174 | 54,991 | 44,195 |
| TOTAL | $1,220,663 | $1,055,251 | $941,709 | $967,786 | $949,785 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 71,030 | 69,009 | 76,850 | 102,753 | 77,140 |
| Other Non-Current Liabilities | 2,951,010 | 2,955,048 | 2,916,443 | 2,894,563 | 2,859,068 |
| TOTAL | $2,952,022 | $2,957,450 | $3,101,949 | $3,082,738 | $3,055,154 |
| Total Liabilities | $4,172,685 | $4,012,701 | $4,043,658 | $4,050,524 | $4,004,939 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 128,981 | 128,381 | 126,492 | 125,946 | 125,493 |
| Common Shares | 1,289 | 1,281 | 1,265 | 1,259 | 1,255 |
| Retained earnings | -7,203,985 | -7,092,415 | -7,075,526 | -7,009,591 | -6,871,721 |
| Other shareholders' equity | -24,826 | -34,637 | -26,988 | -23,375 | -32,339 |
| TOTAL | $32,354 | $-3,067 | $-219,272 | $-220,644 | $-165,866 |
| Total Liabilities And Equity | $4,205,039 | $4,009,634 | $3,824,386 | $3,829,880 | $3,839,073 |